Myocardial viability: known and unknown.

J. J. Bax, Roelf Valkema(Active Medicine (United Kingdom)), G Slavich, R Rambaldi, D Poldermans(Leiden University)

PubMed

March 1, 1998

Cited by 1

Related Papers

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

|European Heart Journal|2011|3.5k

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

|Endocrine Related Cancer|2009|462

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

|Seminars in Nuclear Medicine|2002|433

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

|PubMed|2005|375

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

|Seminars in Nuclear Medicine|2002|347